Sight Sciences (SGHT)
(Delayed Data from NSDQ)
$7.98 USD
+0.37 (4.86%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $7.97 -0.01 (-0.13%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth C Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SGHT 7.98 +0.37(4.86%)
Will SGHT be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for SGHT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SGHT
Sight Sciences, Inc. (SGHT) Reports Q1 Loss, Tops Revenue Estimates
Sight Sciences, Inc. (SGHT) Reports Q4 Loss, Tops Revenue Estimates
SGHT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Sight Sciences (SGHT) to Expand in Europe With New Launch
Ekso Bionics (EKSO) Reports Q3 Loss, Tops Revenue Estimates
Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates
Other News for SGHT
Sight Sciences to Report Second Quarter Financial Results on August 1, 2024
Sight Sciences Announces the Release of its First Sustainability Report
Predictive Oncology, Augmedix, Cue Health among healthcare movers
Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Improved Signs and Symptoms of Dry Eye Disease for TearCare Patients Crossed Over from Restasis
Sight Sciences Announces Publication of a New Analysis from The ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with OMNIĀ® Across Mild, Moderate, and Advanced Glaucoma